Abstract:Pancreatic adenocarcinoma (PAAD), which mortality closely parallels incidence, is lethal and aggressive with a 5-year survival rate of only about 6% (ranging from 2% to 9%). [ 1 ] Most patients with PAAD remain asymptomatic until the disease reaches an advanced stage. Surgical resection is the most effective therapy and it significantly increases the 5-year survival rate to 20%–30%. However, only <20% of patients have the opportunity for resection treatment as most patients are diagnosed at an advanced stage when there is metastasis. [ 2 ] Despite improvements in surgery, radiotherapy, and chemotherapy, the survival rates for PAAD are still poor, even those with the same clinicopathological characteristics have different prognoses and treatment responses, and there are still lacking early diagnostic methods due to nonspecific symptoms and lacking effective testing identification. [ 3 ] Hence, the development of a new strategy to reduce mortality and identify prognostic biomarkers during the early stage is an urgent task. Tang et al constructed a risk signature based on the ferroptosis-related genes and proved that immuno- and chemotherapy combined with a ferroptosis inducer is a feasible therapeutic approach for PAAD. [ 4 ]

Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma